This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
SAN ANTONIO, Texas,
Jan. 22, 2013 /PRNewswire/ -- BINOSTO®
(alendronate sodium) Effervescent Tablet for oral solution 70 mg, was named a "Product to Watch" in the
January 7, 2013, edition of
BioCentury, the Bernstein Report on BioBusiness newsletter. BioCentury is an internationally recognized leader in providing pharmaceutical analysis and data, along with value-added information for biotechnology and pharmaceutical companies. BINOSTO, a product of Mission Pharmacal and the first and only buffered solution of alendronate for the treatment of osteoporosis, was approved in 2012 by the U.S. Food and Drug Administration to treat osteoporosis in postmenopausal women and to increase bone mass in men with osteoporosis.
BINOSTO delivers the gold standard of alendronate sodium, the most broadly prescribed osteoporosis treatment for fracture prevention at the hip and spine, in a pleasant-tasting, once-weekly, buffered solution. BINOSTO also requires 50 percent less water than other alendronate products (4 ounces versus 8 ounces) and, because there is no tablet, patients can rest assured that they will not experience tablet esophagitis. The product represents a true innovation in the delivery of osteoporosis and bone fracture prevention medication, especially for those patients who prefer not to swallow tablets, suffer with dysphagia, or have other medical difficulties swallowing pills.
"Osteoporosis is widespread, with serious consequences for patients, including mortality, which is often seen after suffering a hip fracture. In fact, a 50-year-old woman's lifetime risk of dying from a hip fracture is equal to her risk of dying from breast cancer. And, unfortunately, many people incorrectly consider osteoporosis to be a normal part of aging. That's because it is largely asymptomatic,"[i] said
Sol Epstein, MD, professor of medicine and geriatrics at Mount Sinai School of Medicine in
New York. "But osteoporosis is treatable. With the many new treatment options available, there is no reason for women to suffer the loss of independence and the pain and even mortality associated with osteoporotic fractures."
For anyone with osteoporosis, the best protection against suffering from a fracture is taking medications as prescribed by an authorized healthcare provider. Taken just once a week, strawberry flavored BINOSTO offers an easy-to-take option for patients seeking to decrease their risks of suffering a disabling fracture.